MEHL/Biophile International Corp. v. Milgraum

192 F.3d 1362, 52 U.S.P.Q. 2d (BNA) 1303, 1999 U.S. App. LEXIS 24277, 1999 WL 782709
CourtCourt of Appeals for the Federal Circuit
DecidedSeptember 30, 1999
DocketNo. 99-1038
StatusPublished
Cited by11 cases

This text of 192 F.3d 1362 (MEHL/Biophile International Corp. v. Milgraum) is published on Counsel Stack Legal Research, covering Court of Appeals for the Federal Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
MEHL/Biophile International Corp. v. Milgraum, 192 F.3d 1362, 52 U.S.P.Q. 2d (BNA) 1303, 1999 U.S. App. LEXIS 24277, 1999 WL 782709 (Fed. Cir. 1999).

Opinion

RADER, Circuit Judge.

In this patent infringement action, MEHL/Biophile International Corp., Sel-vae Acquisitions Corp., and Dr. Nardo Zai-as (collectively, MEHL/Biophile) asserted that Dr. Sandy Milgraum, Palomar Medical Technologies, Inc., and Spectrum Medical Technologies, Inc. (Milgraum) infringed U.S. Patent No. 5,059,192 (the ’192 patent). On its motion for summary judgment, Milgraum contended that all of the ’192 patent claims were anticipated by an instruction manual for the Spectrum RD-1200 laser and by a 1987 Journal of Investigative Dermatology article authored by Dr. Luigi Polla and others (the Polla article). The district court agreed that the manual anticipated the claims, granted summary judgment of invalidity, and dismissed the action. See Mehl/Biophile Int’l [1364]*1364Corp. v. Milgraum, 8 F.Supp.2d 434, 47 USPQ2d 1248 (D.N.J.1998). Although this court disagrees that the manual discloses all the elements .of the claimed invention, because the Polla article does, this court affirms.

I.

The ’192 patent, entitled “Method of Hair Depilation,” claims a method for removing hair using a laser. Hairs grows out of hair follicles, tubular apertures in the skin. The collection of germ cells from which hairs grow, known as the papilla, lies at the base of the follicle. The 192 patent claims a method for destroying the papilla,thereby preventing hair regrowth. The written description discloses the use of a Q-switched ruby laser to effect the destruction.

At a meeting of the American Academy of Dermatology, Dr. Zaias visited Spectrum’s booth where Spectrum displayed such a laser, known as the RD-1200. Spectrum sold the RD-1200 for use in removing tattoos. Dr. Zaias recognized that the same principles that govern laser absorption in skin pigmented by a tattoo would also focus laser absorption on the natural skin pigment found in the papilla. More specifically, the papilla contains granules (called melanosomes) of a dark pigment (called melanin). A Q-switched ruby laser aimed at the hair follicle will penetrate the skin and reach the papillary melanin. At a particular wavelength, the laser will heat up and destroy the papilla without damaging surrounding tissue.

Claim 1 of the patent, the only independent claim, reads:

1. A method of hair depilation, comprising the steps of:
a) aligning a laser light applicator substantially vertically over a hair follicle opening, said applicator having an aperture of sufficient area to surround a hair follicle and overlie its papilla;
b) applying through said aperture to the hah* follicle a pulse of laser energy of a wavelength which is readily absorbed by the melanin of the papilla and having a radiant exposure dose of sufficient energy and duration to damage its papilla so that hair regrowth is prevented and scarring of the surrounding, skin is avoided.

Dependent claims 2-6 further specify parameters of the laser light applicator, energy delivery, and the type of laser.

MEHL/Biophile sued Milgraum in the United States District Court for the District of New Jersey for infringement of all the claims of the ’192 patent. Milgraum moved for summary judgment of invalidity based on 35 U.S.C. § 102 (1994), arguing that two prior art references each teach all the limitations of the claims. As noted at the outset, Milgraum relied on the manual for the RD-1200 laser which describes the use of a laser to remove tattoos. The manual teaches the use of a Q-switched ruby laser to remove a tattoo: “[Ejnergy is selectively absorbed only by pigmented chromophores and not surrounding tissue, greatly reducing the risk of scarring.”

Milgraum also relied on the Polla article entitled “Melanosomes Are a Primary Target of Q-Switched Ruby Laser Irradiation in Guinea Pig Skin.” The Polla article documents “the tissue damage induced by Q-switched ruby laser pulses in black, brown, and albino (control) guinea pigs ... in an effort to define the nature and extent of pigmented cell injury.” The method involves epilating guinea pigs with soft wax, holding the aperture of the laser in contact with the skin, and pulsing the laser. Using an electron microscope, the researchers observed “disruption of melanosomes deep in the hair papillae.” '

The district court considered both references, but ultimately rested its decision on the RD-1200 manual. MEHL/Biophile appeals. MEHL/Biophile makes several arguments for disregarding the manual as an anticipating reference. For instance, MEHL/Biophile argues that the manual does not teach use of the laser to remove hair at all. Further MEHL/Biophile contends that the manual does not disclose a substantially vertical alignment, a claim element. As for the Polla article, [1365]*1365MEHL/Biophile argues that the reference relates to guinea pig skin and does not mention hair depilation. In addition, MEHL/Biophile contends that the epilation of the guinea pig backs removed the papilla so the laser treatment could not have damaged the papilla.

II.

This court reviews a district court’s grant of summary judgment by reapplying the standard applicable at the district court. See Conroy v. Reebok Int’l, Ltd., 14 F.3d 1570, 1575, 29 USPQ2d 1373, 1377 (Fed.Cir.1994). Summary judgment is appropriate only when “there is no genuine issue as to any material fact and ... the moving party is entitled to a judgment as a matter of law.” Fed.R.Civ.P. 56(c). In its review, this court draws all reasonable inferences in favor of the non-movant. See Anderson v. Liberty Lobby, Inc., 477 U.S. 242, 255, 106 S.Ct. 2505, 91 L.Ed.2d 202 (1986).

“To anticipate a claim, a prior art reference must disclose every limitation of the claimed invention, either explicitly or inherently.” In re Schreiber, 128 F.3d 1473, 1477, 44 USPQ2d 1429, 1431 (Fed.Cir.1997). As this court’s predecessor stated in In re Oelrich, 666 F.2d 578, 581, 212 USPQ 323, 326 (CCPA 1981) (quoting Hansgirg v. Kemmer, 26 C.C.P.A. 937, 102 F.2d 212, 214, 40 USPQ 665, 667 (1939)) (internal citations omitted):

Inherency, however, may not be established by probabilities or possibilities. The mere fact that a certain thing may result from a given set of circumstances is not sufficient. If, however, the disclosure is sufficient to show that the natural result flowing from the operation as taught would result in the performance of the questioned function, it seems to be well settled that the disclosure should be regarded as sufficient.

Thus, a prior art reference may anticipate when the claim limitation or limitations not expressly found in that reference are nonetheless inherent in it. See In re Oelrich, 666 F.2d at 581; Verdegaal Bros., Inc. v. Union Oil Co. of Cal., 814 F.2d 628

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Engate, Inc. v. Esquire Deposition Services, L.L.C.
331 F. Supp. 2d 673 (N.D. Illinois, 2004)
Emergency Fuel, LLC v. Pennzoil-Quaker State Co.
293 F. Supp. 2d 569 (D. Maryland, 2003)
Schering Corporation v. Geneva Pharmaceuticals
348 F.3d 992 (Federal Circuit, 2003)
Schering Corp. v. Geneva Pharmaceuticals, Inc.
348 F.3d 992 (Federal Circuit, 2003)
System Division, Inc. v. Teknek LLC
59 F. App'x 333 (Federal Circuit, 2003)
3M Unitek Corp. v. Ormco Co.
96 F. Supp. 2d 1042 (C.D. California, 2000)
Mehl/Biophile International Corp. v. Milgraum
192 F.3d 1362 (Federal Circuit, 1999)

Cite This Page — Counsel Stack

Bluebook (online)
192 F.3d 1362, 52 U.S.P.Q. 2d (BNA) 1303, 1999 U.S. App. LEXIS 24277, 1999 WL 782709, Counsel Stack Legal Research, https://law.counselstack.com/opinion/mehlbiophile-international-corp-v-milgraum-cafc-1999.